Search & Analyze

Cipla Ltd.

HealthcarePharmaceuticals & Drugs

www.cipla.com BSE: 500087NSE: CIPLA

₹1,395.95BSE1.34%

07 Sep, 4:01 PM

₹1,395.95

₹1.13L Cr

33.46

3.21

11.83%

₹1,395.95

₹1,377.00

₹1,672.20

₹1,165.55

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,899.80	37.69	4,55,825.66	0.84	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,305.00	84.45	2,47,018.51	0.32	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,913.00	85.68	1,86,874.73	0.77	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,155.00	25.53	1,15,211.69	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
Cipla Ltd. CIPLA	1,395.95	33.46	1,12,773.00	0.93	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,868.25	92.32	1,00,943.83	0.11	362.07	123.94%	2,026.31	29.10%	18.20
LUPIN LTD. LUPIN	2,105.00	17.41	96,254.46	0.86	1,416.98	16.01%	8,276.89	32.04%	28.86
MANKIND MANKIND	2,322.05	46.95	95,911.14	0.04	574.09	29.12%	4,030.59	12.89%	13.24

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	5,478.86	5,260.33	5,375.19	5,828.54	5,810.09	5,739.30	6,328.89	6,678.15	6,163.24	6,693.94	7,051.02	7,072.97	6,729.69	6,957.47	7,589.44	7,074.48	6,541.20	7,119.28
Expenses	4,247.89	4,510.61	4,231.84	4,526.21	4,402.54	4,565.56	4,834.98	4,944.40	4,847.38	4,978.14	5,165.43	5,084.05	5,192.10	5,179.33	5,694.69	5,819.42	5,544.23	5,926.98
	1,230.97	749.72	1,143.35	1,302.33	1,407.55	1,173.74	1,493.91	1,733.75	1,315.86	1,715.80	1,885.59	1,988.92	1,537.59	1,778.14	1,894.75	1,255.06	996.97	1,192.30
	22.47%	14.25%	21.27%	22.34%	24.23%	20.45%	23.60%	25.96%	21.35%	25.63%	26.74%	28.12%	22.85%	25.56%	24.97%	17.74%	15.24%	16.75%
	91.29	6.52	103.43	122.95	114.44	-47.79	136.29	176.32	249.33	160.19	190.61	221.61	289.46	258.56	268.95	-69.57	148.16	210.90
Interest	20.68	18.10	17.81	25.55	31.82	34.36	16.39	25.80	17.59	17.95	15.40	14.64	14.02	14.05	13.18	14.03	13.13	17.03
	247.47	290.31	254.41	299.37	272.11	346.22	239.21	290.04	288.34	246.68	271.74	279.80	308.73	252.72	296.99	278.35	424.94	304.24
	1,052.04	441.81	974.14	1,100.01	1,217.84	743.76	1,376.09	1,593.78	1,256.73	1,610.53	1,788.05	1,906.96	1,493.42	1,769.49	1,853.83	892.80	699.46	1,080.38
	28.06%	16.10%	27.51%	27.51%	33.67%	29.88%	27.47%	27.51%	25.85%	27.01%	27.01%	17.43%	18.70%	27.01%	27.00%	24.48%	22.44%	27.29%
	728.60	362.07	686.40	788.90	800.96	525.65	995.70	1,130.91	939.04	1,177.64	1,302.53	1,570.51	1,221.84	1,297.62	1,351.17	675.80	554.64	789.05
	9.03	4.49	8.51	9.78	9.92	6.51	12.33	14.01	11.63	14.58	16.13	19.45	15.13	16.06	16.73	8.37	6.87	9.77

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	29,719.19	30,937.65	35,415.04	37,038.86	39,011.52
	21,763.34	22,753.12	25,774.09	27,547.62	28,162.59
EXPENDITURE :
Increase/Decrease in Stock	-724.69	-96.00	63.03	-332.10	-743.88
Raw Material Consumed	9,220.29	8,348.28	8,756.54	9,261.09	10,292.99
Power & Fuel Cost	331.03	353.61	364.84	397.18	416.79
Employee Cost	3,529.91	3,830.08	4,310.04	4,832.83	5,366.33
Other Manufacturing Expenses	1,453.22	1,589.90	1,779.35	1,894.12	2,174.08
General and Administration Expenses	1,206.07	1,423.23	1,673.94	1,772.59	1,868.24
Selling and Distribution Expenses	1,670.00	1,694.30	1,724.97	1,834.86	1,934.24
Miscellaneous Expenses	565.55	619.43	810.33	764.21	970.90
	17,251.38	17,762.83	19,483.04	20,424.78	22,279.69
Operating Profit (Excl OI)	4,511.96	4,990.29	6,291.05	7,122.84	5,882.90
	321.73	512.13	746.57	866.93	882.01
	4,833.69	5,502.42	7,037.62	7,989.77	6,764.91
Interest	106.35	109.54	89.88	62.01	54.39
PBDT	4,727.34	5,392.88	6,947.74	7,927.76	6,710.52
	1,051.95	1,172.11	1,051.02	1,106.95	1,210.98
Profit Before Taxation & Exceptional Items	3,675.39	4,220.77	5,896.72	6,820.81	5,499.54
Exceptional Income / Expenses	-182.12	-182.42	-194.82		-275.91
	3,493.27	4,038.35	5,701.90	6,820.81	5,223.63
Provision for Tax	933.80	1,202.86	1,546.59	1,529.76	1,353.84
	2,559.47	2,835.49	4,155.31	5,291.05	3,869.79
Extra items				0.00	0.00
Minority Interest	-29.90	-30.98	-32.17	3.32	17.49
Share of Associate	-12.82	-2.60	-1.59	-21.85	-8.05
Consolidated Net Profit	2,516.75	2,801.91	4,121.55	5,272.52	3,879.23
Profit Balance B/F	13,536.98	15,669.07	18,057.03	21,438.78	25,644.28
Appropriations	16,053.73	18,470.98	22,178.58	26,711.30	29,523.51
Equity Dividend %	250.00%	425.00%	650.00%	800.00%	650.00%
	31.19	34.71	51.05	65.29	48.02
Adjusted EPS	31.19	34.71	51.05	65.29	48.02

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	161.36	161.43	161.47	161.52	161.56
Share Warrants & Outstandings	43.98	61.82	86.54	114.12	62.50
Total Reserves	20,636.35	23,184.53	26,458.42	30,917.81	34,207.89
Reserve excluding Revaluation Reserve	20,636.35	23,184.53	26,458.42	30,917.81	34,207.89
	20,841.69	23,407.78	26,706.43	31,193.45	34,431.95
Minority Interest	275.69	305.76	95.90	95.80	88.29
Secured Loans	376.20	332.46
Unsecured Loans	40.04	-332.46		11.98	117.47
Deferred Tax Assets / Liabilities	-204.87	-293.26	-402.51	-591.34	-747.75
Other Long Term Liabilities	310.45	374.63	355.17	399.63	533.85
Long Term Provisions	100.22	102.16	129.26	148.69	157.56
Total Non-Current Liabilities	622.04	183.53	81.92	-31.04	61.13
Trade Payables	2,508.10	2,534.52	2,473.98	2,837.49	3,229.90
Other Current Liabilities	769.81	1,007.60	890.98	772.99	1,378.59
Short Term Borrowings	393.34	187.90	247.02	80.12	140.50
Short Term Provisions	1,241.62	1,303.25	1,633.79	1,793.36	2,264.60
Total Current Liabilities	4,912.87	5,033.27	5,245.77	5,483.96	7,013.59
Total Liabilities	26,652.29	29,006.74	32,130.02	36,742.17	41,594.96
Gross Block	16,975.58	17,204.76	18,160.54	19,655.92	23,825.03
Less: Accumulated Depreciation	7,318.07	7,994.72	8,573.36	9,707.76	11,343.39
Less: Impairment of Assets	35.60	109.39	93.57	53.02	47.28
Net Block	9,621.91	9,100.65	9,493.61	9,895.14	12,434.36
Capital Work in Progress	382.90	689.17	864.32	1,212.76	1,586.28
Non Current Investments	417.05	572.52	642.21	639.54	543.99
Long Term Investment	417.05	572.52	642.21	639.54	543.99
Long Term Loans & Advances	695.49	849.46	844.39	1,038.36	1,321.80
Other Non Current Assets	440.83	56.03	442.07	203.09	1,105.56
Total Non-Current Assets	11,941.46	11,731.79	12,688.61	13,453.65	17,447.93
Currents Investments	2,194.97	3,089.86	4,807.01	7,293.23	7,679.42
Inventories	5,350.24	5,156.43	5,237.95	5,642.11	6,596.72
Sundry Debtors	3,424.44	4,057.00	4,770.66	5,506.37	5,620.05
Cash and Bank	1,928.48	1,564.62	874.97	799.84	1,307.42
Other Current Assets	305.56	373.99	567.64	526.00	574.70
Short Term Loans and Advances	1,507.14	2,563.16	3,134.22	3,481.42	2,367.55
Total Current Assets	14,710.83	16,805.06	19,392.45	23,248.97	24,145.86
Net Current Assets (Including Current Investments)	9,797.96	11,771.79	14,146.68	17,765.01	17,132.27
Total Assets	26,652.29	29,006.74	32,130.02	36,742.17	41,594.96
Contingent Liabilities	742.84	566.55	633.96	936.04	987.37
Total Debt	824.14	520.36	247.02	92.10	257.97
	257.78	289.24	329.72	384.84	425.47
Adjusted Book Value	257.78	289.24	329.72	384.84	425.47

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	3,675.39	4,220.77	5,896.72	6,820.81	5,223.63
Adjustment	967.47	878.19	640.77	517.74	527.81
Changes In working Capital	-177.46	-559.42	-806.10	-665.47	-225.22
Cash Flow after changes in Working Capital	4,465.40	4,539.54	5,731.39	6,673.08	5,526.22
Cash Flow from Operating Activities	3,325.90	3,237.65	4,133.91	5,004.98	3,940.02
Cash Flow from Investing Activities	-1,871.88	-2,388.51	-2,988.03	-3,691.14	-2,326.13
Cash Flow from Financing Activitie	-1,599.79	-958.29	-1,200.43	-1,292.79	-1,233.65
Net Cash Inflow / Outflow	-145.77	-109.15	-54.55	21.05	380.24
Opening Cash & Cash Equivalents	790.43	658.11	561.33	512.34	542.65
Effect of Foreign Exchange Fluctuations	13.45	12.37	5.56	9.26	92.50
Closing Cash & Cash Equivalent	658.11	561.33	512.34	542.65	1,015.39

Ratios

Valuation

33.46

3.21

18.10

4.03

41.72

435.18

Profitability

11.83

16.00

9.88

15.08

9.92

Leverage & Liquidity

0.01

3.44

97.04

Returns

0.93

1.00

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	30.91	30.92	29.19	29.20	29.19	29.21	29.21	29.21	29.21
	52.69	52.88	54.28	54.42	54.50	54.79	54.64	54.52	54.83
	16.40	16.19	16.52	16.38	16.31	16.00	16.14	16.26	15.95
	69.09	69.08	70.81	70.80	70.81	70.79	70.79	70.79	70.79
No. of Shareholders	4,63,569	4,70,234	5,25,114	5,43,420	5,49,655	5,34,587	5,40,521	5,84,217	5,78,679

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-06-24	Board Meeting	Quarterly Results(Cancelled)
2026-05-13	AGM
2026-05-13	Ex Dividend	Rs.13.0000 per share(650%)Final Dividend	2026-06-05	2026-06-05

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Cipla Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

16 members across the board and senior leadership

Y K Hamied

Chairman

₹2.58 Cr

Mar '26

P R Ramesh

Vice Chairman

₹1.10 Cr

Mar '26

MK Hamied

Vice Chairman

₹2.09 Cr

Mar '22

Abhijit Joshi

Non Executive Director

₹2.59 Cr

Mar '26

Samina Hamied

Executive Vice Chairman

₹9.11 Cr

Mar '22

Adil Zainulbhai

Non Executive Director

₹2.65 Cr

Mar '26

Umang Vohra

Managing Director & Global Chief Executive Officer

₹22.90 Cr

Mar '22

Kamil Hamied

Non Executive Director

₹2.63 Cr

Mar '26

S Radhakrishnan

Non Independent & Non Executive Director

₹2.19 Cr

Mar '22

Balram Bhargava

Non Executive Independent Director

₹92.00 L

Mar '26

Maya Hari

Non Executive Independent Director

₹1.10 Cr

Mar '26

Ashok Sinha

Non Executive Independent Director

₹82.00 L

Mar '22

Sharmila Paranjpe

Non Executive Independent Director

₹98.00 L

Mar '26

Achin Gupta

Managing Director & Global Chief Executive Officer

—

Rajendra Chopra

Company Secretary & Compliance Officer

—

Mandar Purushottam Vaidya

Non Executive Independent Director

₹93.00 L

Mar '26

CIPLA Latest News

News

10 of 10 articles

EQUITY4 Sept 2026 · 10:22

Cipla inches up as its arm partners with Qilu for licensing, supply of QL2107

As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product

COMPANY4 Sept 2026 · 09:45

Cipla’s arm partners with Qilu for licensing, supply of QL2107

As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product

COMPANY31 Aug 2026 · 17:59

Cipla signs licensing agreement with SBP Group’s arm

TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer

COMPANY4 Aug 2026 · 11:59

Cipla's arm gets EIR for manufacturing facility in USA

Earlier, InvaGen had received two inspectional observations in Form 483 from USFDA for said manufacturing facility

EQUITY4 Aug 2026 · 10:12

Cipla informs about update

EQUITY28 Jul 2026 · 10:24

Cipla surges on getting USFDA’s approval for Generic Advair Diskus

The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and COPD

COMPANY28 Jul 2026 · 10:19

Cipla gets USFDA’s approval for Generic Advair Diskus

The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and COPD

EQUITY24 Jul 2026 · 10:41

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Consolidated total income of the company increased by 1.58% to Rs 7,330.18 crore in Q1FY27

EQUITY23 Jul 2026 · 14:38

Cipla informs about press release

COMPANY23 Jul 2026 · 14:11

Cipla reports 39% fall in Q1 consolidated net profit

Consolidated total income of the company increased by 1.58% to Rs 7,330.18 crore in Q1FY27

CIPLA

₹1,395.95

+1.34%